ArticleHeliyon2025
Ya That Somdun improves hepatic steatosis in hyperlipidemic rats.
Article in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Metabolic Status and Expression Level of SREBP mRNA and Mir-33 Among Children Conceived by Assisted Reproductive Technology.International journal of genomics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ya That Somdun (YTS) is a traditional Thai medicine composed of six herbs used as a strengthening tonic. Some of the herbs constituting YTS have antihyperlipidemic and anti-obesity activities. The objective of this study was to elucidate the antihyperlipidemic properties of YTS extract in rats with cholesterol suspension-induced hyperlipidemia. Male Sprague-Dawley rats were subdivided into four groups: normal control (NC), hyperlipidemic control (HC), and those who were administered 100 (YTS100) and 200 mg (YTS200) of YTS/kg body weight (BW). Hyperlipidemic rats were orally administered YTS extract for four consecutive weeks from the fifth week of cholesterol suspension. Serum lipid profiles, body weights, liver and renal functional markers, gene expression involved in lipid metabolism, and liver histopathology were examined. The HC and YTS groups showed a significant increase in body weights compared with the NC group. The YTS100 and YTS200 groups showed no significant difference in serum triglyceride, total cholesterol, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) levels compared with the NC and HC groups. YTS treatment (100 mg/kg BW) downregulated sterol regulatory element binding protein 1c (
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.